Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

EP. 1: An Introduction to the Discussion of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 2: Biomarker-Driven Frontline Ovarian Cancer Treatment

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 3: The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 4: Impact of HRD Status on Frontline Treatment of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 5: Need for Frontline Comparison Trials in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 6: Treating BRCA+ Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 7: Treating Homologous Recombination Proficient Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 8: Personalized Dosing of Niraparib in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 9: NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 10: PAOLA-1 Study Surgical Subset for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 11: Patient Preference for Treatment in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 12: Emerging Combinations in the Frontline Setting of Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 13: Expert Approaches for Treating Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 14: PARP Inhibitors in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 15: New Data for Secondary Surgery in Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 16: Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 17: Antibody Drug Conjugates for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 18: Emerging Therapies in Recurrent Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

EP. 19: Upcoming Clinical Trials for Ovarian Cancer

ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG

July 20th 2020

Episodes

EP. 1: An Introduction to the Discussion of Ovarian Cancer

EP. 2: Biomarker-Driven Frontline Ovarian Cancer Treatment

EP. 3: The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

EP. 4: Impact of HRD Status on Frontline Treatment of Ovarian Cancer

EP. 5: Need for Frontline Comparison Trials in Ovarian Cancer

EP. 6: Treating BRCA+ Ovarian Cancer

EP. 7: Treating Homologous Recombination Proficient Ovarian Cancer

EP. 8: Personalized Dosing of Niraparib in Ovarian Cancer

EP. 9: NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

EP. 10: PAOLA-1 Study Surgical Subset for Ovarian Cancer

EP. 11: Patient Preference for Treatment in Ovarian Cancer

EP. 12: Emerging Combinations in the Frontline Setting of Ovarian Cancer

EP. 13: Expert Approaches for Treating Recurrent Ovarian Cancer

EP. 14: PARP Inhibitors in Recurrent Ovarian Cancer

EP. 15: New Data for Secondary Surgery in Ovarian Cancer

EP. 16: Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

EP. 17: Antibody Drug Conjugates for Ovarian Cancer

EP. 18: Emerging Therapies in Recurrent Ovarian Cancer

EP. 19: Upcoming Clinical Trials for Ovarian Cancer

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma